Synthesis and Structure−Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L

Histone3-lysine79 (H3K79) methyltransferase DOT1L has been found to be a drug target for acute leukemia with MLL (mixed lineage leukemia) gene translocations. A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM. These compounds also show high selectivity (>4500-fold) over three other histone methyltransferases. Structure-activity relationships (SAR) of these compounds for their inhibitory activities against DOT1L are discussed. Potent DOT1L inhibitors exhibit selective activity against the proliferation of MLL-translocated leukemia cell lines MV4;11 and THP1 with EC(50) values of 4-11 μM. Isothermal titration calorimetry studies showed that two representative inhibitors bind with a high affinity to the DOT1L:nucleosome complex and only compete with the enzyme cofactor SAM (S-adenosyl-L-methionine) but not the substrate nucleosome.

[1]  S. Pang,et al.  Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). , 2009, Bioorganic & medicinal chemistry letters.

[2]  R. Blumenthal,et al.  Many paths to methyltransfer: a chronicle of convergence. , 2003, Trends in biochemical sciences.

[3]  Robert E Collins,et al.  Structural and sequence motifs of protein (histone) methylation enzymes. , 2005, Annual review of biophysics and biomolecular structure.

[4]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[5]  Kevin Struhl,et al.  Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain , 2002, Current Biology.

[6]  N. Heerema,et al.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.

[7]  Feng Liu,et al.  A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. , 2011, Nature chemical biology.

[8]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[9]  S. Pang,et al.  Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). , 2008, Bioorganic & medicinal chemistry letters.

[10]  Robert A. Copeland,et al.  Protein methyltransferases as a target class for drug discovery , 2009, Nature Reviews Drug Discovery.

[11]  E. De Clercq,et al.  New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. , 1996, Journal of medicinal chemistry.

[12]  Yuan Yao,et al.  Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. , 2011, Journal of the American Chemical Society.

[13]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[14]  Eric Therrien,et al.  N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). , 2009, Bioorganic & medicinal chemistry letters.

[15]  S. Yajima,et al.  Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes. , 2011, ACS medicinal chemistry letters.

[16]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[17]  B. Blagg,et al.  E. coli MEP synthase: steady-state kinetic analysis and substrate binding. , 2002, Biochemistry.

[18]  Yi Zhang,et al.  Structure of the Catalytic Domain of Human DOT1L, a Non-SET Domain Nucleosomal Histone Methyltransferase , 2003, Cell.

[19]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[20]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[21]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[22]  K. O. Elliston,et al.  Chemogenetic Analysis of Human Protein Methyltransferases , 2011, Chemical biology & drug design.

[23]  S. Frye,et al.  Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. , 2011, Journal of medicinal chemistry.

[24]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[25]  T. Palzkill,et al.  Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase. , 2012, ACS medicinal chemistry letters.

[26]  P. Cole,et al.  Chemical probes for histone-modifying enzymes. , 2008, Nature chemical biology.

[27]  Anton Simeonov,et al.  Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. , 2010, Journal of medicinal chemistry.

[28]  Anton Simeonov,et al.  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. , 2009, Journal of medicinal chemistry.

[29]  R. Coulombe,et al.  Pharmacokinetics of the antiviral agent 3-deazaneplanocin A , 1995, European Journal of Drug Metabolism and Pharmacokinetics.